Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

The unintended consequences of government price setting in Medicare Part D

Nicole Longo
Yesterday, the administration released the government-set prices for the first 10 medicines selected under the Inflation Reduction Act (IRA). The announcement left out important context about what is already happening in Medicare Part D because of the changes in the IRA and how Medicare patients are negatively impacted.
Doctor speaking with patient with child

Voters across all 50 states want state policymakers to focus on health insurance and PBM practices

Headshot of Reid Porter, Senior Director of State Public Affairs at PhRMA
Reid Porter
Americans are also concerned by the unintended consequences state price setting policies.

PhRMA launches new ad in campaign exposing ways middlemen drive up costs

Alex Schriver bio picture
Alex Schriver
PBMs and health insurers decide what medicines you can get, and they set the price you pay at the pharmacy. At the same time, over half of every dollar spent on medicines goes to these middlemen and others.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.